You are here: Industry Insights > schizophrenia

News List

Biogen acquires Schizophrenia investigational drug candidate form Pfizer biospectrumasia
March 16, 2018
The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments
Biogen to acquire first-in-class Phase IIb ready asset for cognitive impairment cphi-online
March 14, 2018
PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.
Lundbeck partners with Vanderbilt University on schizophrenia research project pharmafile
January 11, 2018
Danish pharmaceutical firm Lundbeck has signed a separate licensing and research collaboration agreement with Tennessee’s Vanderbilt University to develop a novel solution in the treatment of schizophrenia, it has emerged.
Schizophrenia drugs market will be worth US$7.9 billion by 2022 pharmaasia
November 20, 2017
The report expects the schizophrenia market to be driven by improved drug delivery technologies, LAI availability and more patients seeking treatment.
FDA approves Vraylar in the maintenance treatment of schizophrenia europeanpharmaceuticalreview
November 14, 2017
The FDA has approved the supplemental New Drug Application for Vraylarfor the maintenance treatment of adults with schizophrenia…
Adult patients with Schizophrenia in Singapore to benefit from the first three-monthly long-acting biospectrumasia
October 11, 2017
This is the first and only treatment administered four times a year allows schizophrenia patients to focus on other aspects of their lives and rehabilitation plan.
Allergan receives FDA’s RTF letter for Vraylar sNDA to treat schizophrenia pharmaceufical-technology
September 27, 2017
Schizophrenia is a chronic and disabling disorder that leads to positive symptoms, including hallucinations, delusions and thought disorders, and negative symptoms, such as loss of motivation and social withdrawal.
FDA Approves Two-Month Aristada for Treatment of Schizophrenia drugs.com
June 08, 2017
Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Braeburn achieves endpoints in implant study to treat Schizophrenia europeanpharmaceuticalreview
May 08, 2017
Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia or schizoaffective disorder and stabilized on oral risperidone to BB0817 (risperidone) implant has met its prima
Health Canada Approves Otsuka and Lundbeck's REXULTI™ as a Treatment for Schizophrenia in Adults americanpharmaceuticalreview
February 22, 2017
Otsuka Pharmaceutical Co. and Lundbeck Canada announced that Health Canada issued a Notice of Compliance for REXULTI™ (brexpiprazole) for the treatment of schizophrenia in adults. REXULTI™ was discovered by Otsuka and co-developed with Lundbeck. It

Previous page 1 2 3 4 5 Next page